Alpelisib (ALP) plus endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2-Negative (HER2-) advanced breast cancer (ABC): Additional study cohort in BYLieve

被引：0
|
作者：
Ciruelos, E. [1 ]
Lerebours, F. [2 ]
Ruiz Borrego, M. [3 ]
Bachelot, T. [4 ]
Polikoff, J. [5 ]
Chia, S. [6 ]
Juric, D. [7 ]
Turner, N. [8 ,9 ]
Ridolfi, A. [10 ]
Sophos, N. [11 ]
Cooper, B. [12 ]
Thuerigen, A. [13 ]
Rugo, H. S. [14 ]
机构：
[1] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[2] Hop Rene Huguenin, Dept Oncol, Inst Curie, St Cloud, France
[3] Hosp Univ Virgen del Rocio, Dept Oncol, Seville, Spain
[4] Ctr Leon Berard, Dept Oncol, Lyon, France
[5] Kaiser Permanente Southern Calif, Dept Oncol, San Diego, CA USA
[6] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[7] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA
[8] Inst Canc Res, Dept Oncol, London, England
[9] Royal Marsden Hosp, London, England
[10] Novartis Pharmaceut, Rueil Malmaison, France
[11] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA
[12] Novartis Pharmaceut, Oncol Med Affairs, E Hanover, NJ USA
[13] Novartis Pharmaceut, Oncol Med Affairs, Basel, Switzerland
[14] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388TiP
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
    Rugo, Hope S.
    Borrego, Manuel Ruiz
    Chia, Stephen K. L.
    Juric, Dejan
    Turner, Nicholas C.
    Drullinsky, Pamela
    Lerebours, Florence
    Bianchi, Giulia Valeria
    Nienstedt, Carolyn C.
    Ridolfi, Antonia
    Thuerigen, Astrid
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
    Cardoso, F.
    Juric, D.
    Lerebours, F.
    Krop, I.
    Borrego, M. Ruiz
    Neven, P.
    Park, Y. H.
    Yardley, D.
    Jhaveri, K.
    Arce, C.
    Gu, E.
    Akdere, M.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S206 - S207
  • [3] Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor- positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
    Juric, Dejan
    Loibl, Sibylle
    Andre, Fabrice
    Mingorance, J. Ignacio Delgado
    Forget, Frederic
    Levy, Christelle
    Masuda, Norikazu
    Campone, Mario
    Conte, Pier Franco
    Iwata, Hiroji
    Mayer, Ingrid A.
    Rugo, Hope S.
    Wilke, Celine
    Ridolfi, Antonia
    Lteif, Agnes
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
    Chia, Stephen
    Neven, Patrick
    Ciruelos, Eva M.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Park, Yeon Hee
    Juric, Dejan
    Turner, Nicholas C.
    Chattar, Yogesh
    Patino, Heather
    Akdere, Murat
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) plus fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
    Burnette, S.
    Poehlein, E.
    Lee, H-J.
    Force, J.
    Westbrook, K.
    Moore, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S470 - S470
  • [6] Real-world effectiveness of alpelisib (ALP) plus fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2 negative (HER2-) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
    Turner, S.
    Chia, S. K. L.
    Kanakamedala, H.
    Hsu, W-C.
    Park, J.
    Chandiwana, D.
    Ridolfi, A.
    Yu, C-L.
    Zarate, J. P.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S366 - S366
  • [7] Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
    Chia, Stephen K. L.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Juric, Dejan
    Bachelot, Thomas
    Rugo, Hope S.
    Ciruelos, Eva M.
    Lerebours, Florence
    Prat, Aleix
    Akdere, Murat
    Arce, Christina
    Gu, Ennan
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Alpelisib plus letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results
    Rugo, Hope S.
    Lerebours, Florence
    Juric, Dejan
    Turner, Nicholas
    Chia, Stephen
    Drullinsky, Pamela
    Prat, Aleix
    Villanueva Vazquez, Rafael
    Akdere, Murat
    Arce, Christina
    Shen, Yu-Ming
    Ciruelos, Eva
    CANCER RESEARCH, 2021, 81 (04)
  • [9] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
    Engel-Nitz, Nicole M.
    Hao, Yanni
    Rogerio, Jaqueline Willemann
    Turnbull, James D.
    Rey, Gabriel Gomez
    Sullivan, Jane
    Rossof, Arthur H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [10] Alpelisib (ALP) plus fulvestrant (FUL) in hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial
    Campone, M.
    Rugo, H. S.
    Rubovszky, G.
    Andre, F.
    Loibl, S.
    Iwata, H.
    Conte, P. F.
    Mayer, I.
    Juric, D.
    Yamashita, T.
    Lorenzo, I.
    Ridolfi, A.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 122 - +
12345